Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to $2.1 million.

  • IDEAYA Biosciences' Cash from Financing Activities fell 2262.99% to $2.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $29.8 million, marking a year-over-year decrease of 9560.49%. This contributed to the annual value of $29.8 million for FY2025, which is 9560.49% down from last year.
  • As of Q4 2025, IDEAYA Biosciences' Cash from Financing Activities stood at $2.1 million, which was down 2262.99% from $301000.0 recorded in Q3 2025.
  • IDEAYA Biosciences' 5-year Cash from Financing Activities high stood at $349.1 million for Q1 2024, and its period low was $301000.0 during Q3 2025.
  • In the last 5 years, IDEAYA Biosciences' Cash from Financing Activities had a median value of $21.1 million in 2021 and averaged $65.6 million.
  • Per our database at Business Quant, IDEAYA Biosciences' Cash from Financing Activities soared by 12344117.65% in 2021 and then tumbled by 9989.49% in 2025.
  • IDEAYA Biosciences' Cash from Financing Activities (Quarter) stood at $688000.0 in 2021, then tumbled by 52.91% to $324000.0 in 2022, then surged by 43385.8% to $140.9 million in 2023, then crashed by 98.05% to $2.8 million in 2024, then decreased by 22.63% to $2.1 million in 2025.
  • Its Cash from Financing Activities stands at $2.1 million for Q4 2025, versus $301000.0 for Q3 2025 and $1.2 million for Q2 2025.